文献速递抗栓抗凝管理治疗药物监测与药物基因组学肝肾功能剂量调整

达比加群峰谷浓度系统综述与荟萃分析

A systematic review and meta-analysis of dabigatran peak and trough concentration in adults.
PubMed 文献 · Br J Clin Pharmacol · 2022-06-16

该系统综述与荟萃分析纳入15项观察性研究共1226例患者,汇总真实世界中达比加群的峰浓度与谷浓度。合并峰浓度为133 ng/mL(95%CI:113-154),合并谷浓度为80 ng/mL(95%CI:69-91)。年龄与谷浓度显著相关,体重和肌酐清除率与峰浓度显著相关,液相色谱-串联质谱法测得浓度高于血凝块凝血酶抑制剂法。

要点

  • 真实世界达比加群合并峰浓度133 ng/mL,合并谷浓度80 ng/mL。
  • 年龄与谷浓度显著相关,体重和肌酐清除率与峰浓度显著相关。
  • 液相色谱-串联质谱法测得浓度高于血凝块凝血酶抑制剂法。

核心结论

  • 真实世界研究中达比加群合并峰浓度为133 ng/mL(95%CI:113-154),合并谷浓度为80 ng/mL(95%CI:69-91)。
  • 年龄与谷浓度显著相关,体重和肌酐清除率与峰浓度显著相关。
  • 合并浓度与若干指南建议的达比加群目标范围一致。

研究设计与样本

  • 系统综述与荟萃分析,纳入报告达比加群峰浓度或谷浓度及患者性别、年龄或体重等临床特征的观察性研究。
  • 共纳入15项研究、1226例患者;峰浓度合并分析n=655,谷浓度合并分析n=1010。

主要发现

  • 合并峰浓度为133 ng/mL(95%CI:113-154,I2=86%,n=655)。
  • 合并谷浓度为80 ng/mL(95%CI:69-91,I2=93%,n=1010)。
  • 荟萃回归提示年龄与谷浓度显著相关,体重和肌酐清除率与峰浓度显著相关。
  • 亚组结果显示液相色谱-串联质谱法测得达比加群浓度高于血凝块凝血酶抑制剂法。

关键数值与推荐

  • 合并峰浓度133 ng/mL(95%CI:113-154),合并谷浓度80 ng/mL(95%CI:69-91)。
  • 峰浓度与谷浓度的合并值均与若干指南提出的达比加群目标范围一致。

临床怎么用

  • 在需要测量达比加群浓度的临床情形下,可以上述真实世界合并峰谷浓度作为参考。
  • 解读浓度时应考虑年龄对谷浓度、体重和肌酐清除率对峰浓度的影响。
  • 不同检测方法所得浓度存在差异,液相色谱-串联质谱法结果高于血凝块凝血酶抑制剂法。

局限性

  • 纳入研究间异质性较高(峰浓度I2=86%,谷浓度I2=93%)。
  • 达比加群浓度与临床结局的相关性尚需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dabigatran etexilate is an oral direct thrombin inhibitor used in preventing thromboembolism in patients with atrial fibrillation and several other conditions. Routine dabigatran concentration monitoring is not recommended in clinical practice; however, measurement of dabigatran concentration may be required in several conditions. This study aims to pool the peak and trough dabigatran concentration from real-world studies. A systematic review was performed to identify studies that measured the peak and trough dabigatran concentrations. Observational studies reporting dabigatran peak or trough concentrations and patients' clinical characteristics of either sex, age or weight were included. Random-effect meta-analyses and metaregression were conducted to pool dabigatran concentrations and to identify the correlation between factors affecting dabigatran concentrations. Fifteen studies with a total of 1226 patients were included. The pooled peak dabigatran concentration was 133 ng/mL (95% CI: 113-154, I2 = 86%, n = 655), while the pooled dabigatran trough concentration was 80 ng/mL (95% CI: 69-91, I2 = 93%, n = 1010). Metaregression analyses suggested that age is significantly correlated to trough concentration, while body weight and creatinine clearance significantly correlated to peak concentration. Subgroup results revealed that dabigatran concentration when measured with liquid chromatography-tandem mass spectrometry was higher than haemoclot thrombin inhibitor assay. Several guidelines have proposed dabigatran concentrations target range and the pooled dabigatran concentrations were in line with the suggested range. Further studies to correlate dabigatran concentrations and clinical outcomes is warranted to improve the safety and efficacy monitoring of dabigatran therapy.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ng JW, Mohd Tahir NA, Chin PKL, et al. A systematic review and meta-analysis of dabigatran peak and trough concentration in adults. Br J Clin Pharmacol. 2022. PMID: 35665523. doi:10.1111/bcp.15431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。